1 |
Siu LK, Yeh KM, Lin JC, et al. Klebsiella pneumoniae liver abscess: a new invasive syndrome[J]. Lancet Infect Dis, 2012,12(11): 881-887.
|
2 |
Holt KE, Wertheim H, Zadoks RN, et al. Genomic analysis of diversity, population structure, virulence, and antimicrobial resistance in Klebsiella pneumoniae, an urgent threat to public health[J]. Proc Natl Acad Sci U S A, 2015,112(27): E3574-E3581.
|
3 |
Nordmann P, Cuzon G, Naas T. The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria[J]. Lancet Infect Dis, 2009,9(4): 228-236.
|
4 |
Pitout JD, Laupland KB. Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern[J]. Lancet Infect Dis, 2008,8(3): 159-166.
|
5 |
Wang Y, Lei H, Zhang Y, et al. Epidemiology of carbapenem-resistant Klebsiella pneumoniae bloodstream infections after renal transplantation from donation after cardiac death in a Chinese hospital: a case series analysis[J]. Antimicrob Resist Infect Control, 2018,7: 66.
|
6 |
Akova M, Daikos GL, Tzouvelekis L, et al. Interventional strategies and current clinical experience with carbapenemase-producing Gram-negative bacteria[J]. Clin Microbiol Infect, 2012,18(5): 439-448.
|
7 |
Wyres KL, Lam MMC, Holt KE. Population genomics of Klebsiella pneumoniae[J]. Nat Rev Microbiol, 2020,18(6): 344-359.
|
8 |
李文磊,武聚山,贾哲,等. 肝移植术后耐碳青霉烯肺炎克雷伯菌感染危险因素分析[J/CD].中华移植杂志:电子版,2021,15(6): 347-352.
|
9 |
Liang H, Zhang P, Yu B, et al. Machine perfusion combined with antibiotics prevents donor-derived infections caused by multidrug-resistant bacteria[J]. Am J Transplant, 2022,22(7):1791-1803.
|
10 |
Wang ZQ, Guo ZL, Feng H, et al. Treatment of donor-derived carbapenem-resistant Klebsiella pneumoniae infection after renal transplantation with tigecycline and extended-infusion meropenem[J]. Curr Med Sci, 2021,41(4):770-776.
|
11 |
Okon E, Engell C, van Manen R, et al. Tigecycline-related pancreatitis: a review of spontaneous adverse event reports[J]. Pharmacotherapy, 2013,33(1):63-68.
|
12 |
Karakonstantis S, Kritsotakis EI, Gikas A. Treatment options for K. pneumoniae, P. aeruginosa and A. baumannii co-resistant to carbapenems, aminoglycosides, polymyxins and tigecycline: an approach based on the mechanisms of resistance to carbapenems[J]. Infection, 2020,48(6): 835-851.
|
13 |
Temkin E, Torre-Cisneros J, Beovic B, et al. Ceftazidime-avibactam as salvage therapy for infections caused by carbapenem-resistant organisms[J]. Antimicrob Agents Chemother, 2017,61(2):e01964-e01966.
|
14 |
吴佳晋,李大伟,张明,等. 肾移植术后供肾来源耐碳青霉烯类肺炎克雷伯菌感染九例诊疗经验[J]. 中华器官移植杂志,2019,40(6):334-338.
|
15 |
Soriano A, Carmeli Y, Omrani AS, et al. Ceftazidime-avibactam for the treatment of serious Gram-negative infections with limited treatment options: a systematic literature review[J]. Infect Dis Ther, 2021,10(4): 1989-2034.
|
16 |
马红叶,刘哲,张蕾,等. 医院2014—2020年肺炎克雷伯菌临床分布及耐药性研究[J]. 中国医药,2022,17(1):88-92.
|